SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 6206 | $1.4M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 3457 | $810K |
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 5704 | $1.3M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 6731 | $1.6M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 16187 | $3.8M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-19 | Open-market sell | 6244 | $1.5M |
| Scherer Mary C. | Chief Accounting Officer | 2026-08-19 | Open-market sell | 100 | $24K |
| Scherer Mary C. | Chief Accounting Officer | 2026-08-19 | Open-market sell | 2202 | $523K |
| Alt Aaron E | Chief Financial Officer | 2026-08-18 | Open-market sell | 3115 | $731K |
| Alt Aaron E | Chief Financial Officer | 2026-08-18 | Open-market sell | 12228 | $2.9M |
| Alt Aaron E | Chief Financial Officer | 2026-08-18 | Open-market sell | 13685 | $3.2M |
| Alt Aaron E | Chief Financial Officer | 2026-08-18 | Open-market sell | 12972 | $3.1M |
| Greene Michelle D. | Chief Information Officer | 2026-08-18 | Open-market sell | 2500 | $586K |
| Greene Michelle D. | Chief Information Officer | 2026-08-18 | Open-market sell | 4952 | $1.2M |
| Greene Michelle D. | Chief Information Officer | 2026-08-18 | Open-market sell | 3512 | $830K |
| Greene Michelle D. | Chief Information Officer | 2026-08-18 | Open-market sell | 686 | $163K |
| Hollar Jason M. | Chief Executive Officer | 2026-08-18 | Open-market sell | 21407 | $5.0M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-18 | Open-market sell | 29915 | $7.0M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-18 | Open-market sell | 16208 | $3.8M |
| Hollar Jason M. | Chief Executive Officer | 2026-08-18 | Open-market sell | 12470 | $3.0M |
Fiscal period ending 2026-06-30 versus 2025-06-30 — view filing on EDGAR →
A ~$1.6B IRS tax liability (two NOPAs), $200M tariff exposure, expanded litigation/compliance risks, and a $184M goodwill impairment collectively push the risk profile materially higher. The macro_geopolitical and ma_strategic "easing" signals are offset by new, more specific disclosures in the same themes, suggesting reorganization of disclosure rather than genuine risk resolution. Competitive pressures and Inflation Reduction Act headwinds add further breadth to an already worsening picture.
4 company-specific · 2 eased/removed · 2 common-mode
IRS issued two NOPAs in fiscal 2026 challenging ~$400M self-insurance deduction and ~$160M restructuring transaction, totaling ~$1.6B potential liability plus interest. Concrete, quantified tax exposure materially worsened.
We could be subject to adverse changes in the tax laws or challenges to our tax positions. We are a large multinational corporation with operations in the United States and many foreign countries. As…
New disclosure of material MSO acquisition strategy with $184M goodwill impairment, regulatory risks limiting practice ownership, and integration execution risks.
Our results of operations and financial condition may be adversely affected by risks associated with our MSO business and our ability to execute our strategy. Since fiscal 2025, we have completed a…
New disclosure of $200M tariff exposure, $100M net benefit reversal, and ongoing tariff risks under multiple trade acts with competitive and supply chain implications.
Industry & Economic Risks Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency, and other risks could disrupt our global operations or…
Expanded disclosure of compliance risks, internal investigations, qui tam actions, and regulatory subpoenas. New detail on product quality issues and corrective actions materially broadens litigation exposure.
The outcome or resolution of certain legal proceedings could adversely impact our cash flows or results of operations. Due to the nature of our business, which includes the distribution of controlled…
Removal of material acquisition-related risks including physician practice ownership, fraud/abuse exposure, and integration challenges suggests successful execution or strategic pivot away from this business line.
Our results of operations and financial condition may be adversely affected by risks associated with entering new lines of business, and our ability to execute our strategy. As a result of our…
Removal of detailed disclosure of tariff, trade policy, currency, and supply chain risks (including UFPLA constraints) suggests company no longer views these as material threats to operations or financial results.
Industry & Economic Risks Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency, and other risks could disrupt our global operations or…
Added specific regulatory risks: supply chain integrity requirements, potential compliance costs and penalties, and explicit acknowledgment that Inflation Reduction Act is adversely impacting revenue.
Changes to the U.S. healthcare environment may not be favorable to us. Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical…
Expanded scope: added competitive pressures, new business models, new entrants, pricing pressure, and margin erosion risks beyond consolidation alone.
We could continue to be impacted by the effects of competitive pressures and industry consolidation, and changes in our relationships with significant customers could adversely affect us. As…
Fiscal period ending 2025-06-30 versus 2024-06-30 — view filing on EDGAR →
Pervasive, broad-based risk deterioration spans six distinct themes — legal/litigation, supply chain, regulatory, M&A, competitive, and macro — with no offsetting easing. The combination of a $650M+ opioid settlement, active DOJ investigation (Anti-Kickback/False Claims), $966M IRS audit exposure, FDA enforcement action, CVS concentration jumping to 30% of revenue, and newly acquired physician-practice businesses carrying their own fraud and regulatory tail risk constitutes a materially worsened risk profile. Supply chain cost pressures are now explicitly open-ended through 2025, and cybersecurity, tariff, and reimbursement headwinds compound an already stressed picture.
12 company-specific · 2 common-mode
New disclosure of major opioid litigation, $650M+ settlement, ongoing private lawsuits, compliance costs, and reputational risk. Material legal and operational exposure.
Opioid-related legal proceedings and the NOSA we have entered into could have additional or unexpected negative effects on our results of operations or business . Cardinal Health, along with other…
New disclosure of FDA warning letter (April 2024) for non-compliant syringes from Chinese supplier. Concrete regulatory enforcement action with operational and financial consequences.
Product quality issues could adversely affect operations, profitability, cash flows, and our financial condition. As described in the "Business" section, products that we manufacture, source…
New disclosure of material litigation and product liability exposure, including ongoing IVC filter settlements, consent decrees, and OIG compliance obligations affecting cash flows and operations.
The outcome or resolution of certain legal proceedings could adversely impact our cash flows or results of operations. Due to the nature of our business, which includes the distribution of controlled…
Newly disclosed operational and supply chain risks spanning IT systems, critical facilities, distribution networks, manufacturing, and data governance. Substantive risks to order fulfillment, inventory management, and competitive position.
Business & Operational Risks Our business and operations depend on the proper functioning of information systems, critical facilities, and distribution networks and could be negatively impacted by…
New disclosure of material cybersecurity risk. Company handles sensitive health and financial data; acknowledges past attacks, increasing AI-powered threats, and recent acquisitions adding incremental risk. Insurance becoming costly and limited.
Our business and results of operations could be adversely affected if we experience a material cyber-attack or other systems breach. Cybersecurity incidents and attacks resulting in unauthorized…
CVS concentration increased from 24% to 30% of revenue post-OptumRx loss. Heightened customer concentration risk materially worsens financial vulnerability.
Our sales and credit concentration is significant. In fiscal year 2025, CVS Health was our largest customer. CVS Health accounted for 30 percent of our fiscal 2025 revenue and 26 percent of our gross…
New material risk from recently announced acquisitions entering physician practice support/management. Discloses fraud/abuse, regulatory, litigation, and cybersecurity risks specific to new business lines.
Our results of operations and financial condition may be adversely affected by risks associated with entering new lines of business, and our ability to execute our strategy. As a result of our…
New disclosure of active DOJ investigation (CID) into Anti-Kickback Statute and False Claims Act violations, plus EtO litigation and regulatory enforcement. Material compliance and legal risk.
Legal, Regulatory, & Compliance Risks Our business is subject to rigorous regulatory and licensing requirements. As described in the "Business" section, products that we manufacture, source…
New disclosure of material tax risks: $966M CARES Act refund under IRS audit, uncertain opioid-related tax deductions, and exposure to OBBBA and international tax changes affecting effective tax rate and cash flows.
We could be subject to adverse changes in the tax laws or challenges to our tax positions. We are a large multinational corporation with operations in the United States and many foreign countries. As…
New regulatory risk disclosed: state legislation limiting corporate ownership of physician practices could impair recently acquired businesses and strategy execution.
Our ability to complete, integrate, and manage acquisitions could impact our strategic objectives and financial condition. From time to time, we acquire or look to acquire other businesses that…
Supply chain cost pressures extended through 2025 and language escalated from normalization expectations to "significantly increase or become subject to additional variability," signaling worsened outlook.
We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs, availability, and regulatory risk associated with these…
Added explicit risk of customer relationship changes and disclosed onboarding delays from external factors, escalating competitive and operational risk.
We could continue to suffer the adverse effects of competitive pressures, and changes in our relationships with significant customers could adversely affect us. As described in greater detail in the…
New disclosure of material healthcare regulatory and pricing risks: MFN Executive Order, OBBBA adoption, 340B program litigation, and reimbursement pressure directly threaten pharma segment revenue and profitability.
Changes to the U.S. healthcare environment may not be favorable to us. Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical…
Escalated tariff risk with concrete examples (recent U.S. tariffs, retaliatory actions, UFPLA). Added competitive disadvantage and reimbursement risk. Documented supply constraints already experienced.
Industry & Economic Risks Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency, and other risks could disrupt our global operations or…
Cardinal Health entered into a new $4.0 billion unsecured revolving credit facility on August 7, 2026, replacing existing credit facilities. The facility includes customary financial covenants and events of default, and will be used for general corporate purposes.
View raw filing on EDGAR →Cardinal Health issued a news release on August 11, 2026, announcing fourth quarter and fiscal year 2026 financial results, including Q4 revenue of $63.7 billion and FY revenue of $254.2 billion, along with GAAP and non-GAAP EPS figures and fiscal year 2027 guidance. The company will host a webcast with the CEO and CFO to discuss the results and outlook.
View raw filing on EDGAR →The filing discloses the appointment of Anita Zielinski as Chief Accounting Officer of Cardinal Health, effective November 5, 2026, with her joining as Senior Vice President Finance on September 16, 2026. While the disclosure also mentions Mary Scherer's continued service through the transition date, the principal action is Zielinski's appointment to a named executive officer role. The detailed background, compensation package (including $750,000 sign-on bonus and $1,000,000 in restricted share units), and effective dates confirm this is a material executive appointment.
View raw filing on EDGAR →